Paolo Tarantino

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Paolo Tarantino
Dec 29, 2024, 10:16 | Insight
Paolo Tarantino: Top 10 ADC Milestones of 2024
Paolo Tarantino, Clinical Research Fellow at the Dana-Farber Cancer Institute, shared on X: “2024 has…
Dec 28, 2024, 15:46 | Drugs
Paolo Tarantino: Dato-DXd is now approved in Japan for HR+/HER2- MBC
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post…
Dec 25, 2024, 22:43 | History
Raffaele Colombo: A record 77 new ADCs entered clinical development in 2024
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., shared a post on X…
Dec 23, 2024, 15:13 | Insight
5 Articles suggested by Vivek Subbiah
Vivek Subbiah shared a few must-reads papers: 1. Prenatal cfDNA Sequencing and Incidental Detection of…
Dec 23, 2024, 12:23 | Science
Paolo Tarantino: PostMONARCH is out in Journal of Clinical Oncology
A recent paper by Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship,…
Dec 23, 2024, 12:00 | Blog
Bertrand Delsuc: Refreshed Breast Cancer Map
Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X: "Daiichi Sankyo AZN…
Dec 21, 2024, 12:39 | Insight
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer
Dan Nicolson, Director of Biopharma Business Development at Personalis, Inc., shared a post on Linkedin:…
Dec 21, 2024, 12:14 | Blog
Paolo Tarantino: Ending of a terrific 3-year cycle of PhD at The University of Milan
Paolo Tarantino, Research Fellow, Dana-Farber Cancer Institute, shared a post on LinkedIn: "Ending of a…
Dec 21, 2024, 11:18 | Blog
Jose Fernando Moura: Pivotal SABCS24 summary hosted by Cancer Network
Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and…
Dec 21, 2024, 03:09 | Career
Paolo Tarantino: I have completed a PhD in Clinical Research at the University of Milan
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared a post on LinkedIn: "I am…
Dec 19, 2024, 02:43 | Blog
Paolo Tarantino: The highly awaited Breast Cancer trials with positive results
Paolo Tarantino, PhD in clinical research at the University of Milan, shared a post on…
Dec 19, 2024, 02:01 | Science
Paolo Tarantino: Time to move beyond the one-size-fits all paradigm for residual disease
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post…
Dec 18, 2024, 16:11 | Blog
Paolo Tarantino: Proud to be part of international group of ESMO Ambassadors
Paolo Tarantino, PhD in clinical research at the University of Milan, shared a post on…
Dec 18, 2024, 13:40 | Blog
Cancer Network - Insightful and thought-provoking discussion to recap the SABCS2024
Cancer Network shared on X: "Join Paolo Tarantino and Matteo Lambertini on Wednesday, December 18th…
Dec 17, 2024, 01:16 | Blog
Paolo Tarantino: LAG3 blockade adds upon PD1 blockade in melanoma
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post by Akhil Santhosh,…
Dec 16, 2024, 17:51 | Insight
Best of 2024 SABCS - San Antonio Breast Cancer Symposium
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 16, 2024, 04:11 | Insight
Highlights from Day 4 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) took place from December 10th to 13th,…
Dec 15, 2024, 08:38 | Blog
EMBER3 data in the context of other treatment options in ET-pretreated HR+/HER2- MBC
Paolo Tarantino, Working towards a PhD in clinical research at the University of Milan, shared…
Dec 14, 2024, 17:00 | Insight
Insights on PATINA trial from SABCS 2024
Pre-clinical data showed that CDK 4/6 inhibition plays a role in HER2+ disease. Phase 2…
Dec 14, 2024, 16:31 | Blog
Stefan Lukac: Our work regarding relevance of carbon footprint in the breast cancer trials at SABCS 2024
Stefan Lukac, Gynecologist at University Hospital Ulm, shared on LinkedIn: “It was my honor to…
Dec 14, 2024, 15:53 | Insight
Highlights from SABCS24 by Paolo Tarantino
The San Antonio Breast Cancer Symposium (SABCS) 2024 took place from December 10-13 in San…
Dec 13, 2024, 19:52 | Blog
Insights on EMBER3 trial from SABCS 2024
Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…
Dec 12, 2024, 20:39 | Blog
Ada Waks on the management of small HER2+ breast cancers
Paolo Tarantino shared on X: "Terrific talk on the management of small HER2+ breast cancers by…
Dec 12, 2024, 20:39 | Blog
Imlunestrant + abemaciclib likely to become a new 2L treatment option for HR+/HER2- Metastatic breast cancer
Paolo Tarantino shared on X: "Practice-changing data from EMBER3 presented by Komal Jhaveri and concomitantly published…
Dec 12, 2024, 20:39 | Blog
Paolo Tarantino: SHR-A1811 x8 +/- pyrotinib vs TCHP for stage III HER2+ early breast cancer
Paolo Tarantino shared on X: "Impressive results from a randomized trial of neoadjuvant SHR-A1811 x8 (aka…
Dec 12, 2024, 14:12 | Blog
SABCS24 Day 2 Highlights from Oncology Brothers
Oncology Brothers posted on X: "SABCS24 Day 2 Highlights 1. EMBER3: Oral SERD in HR+…
Dec 12, 2024, 13:36 | Blog
Paolo Tarantino: What is the activity of different treatment regimens after progression on T-DXd for MBC?
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, posted on X: "What is the activity…
Dec 12, 2024, 13:26 | Insight
Highlights from Day 2 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 11, 2024, 19:12 | Insight
Highlights from Day 1 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 11, 2024, 16:18 | Opinion
Paolo Tarantino: SABCS 2024 day 1 kicked off with FDA Oncology special session on drug approval
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, posted on X: "SABCS24 day 1 kicks…
Dec 10, 2024, 07:40 | Blog
Paolo Tarantino: Upcoming SABCS24 session on the future of ADCs
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn: “Small preview from…
Dec 8, 2024, 06:53 | Insight
The role of ADCs in the treatment of patients with Breast Cancer Brain Metastases - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X, about a recent paper by Stacey…
Dec 7, 2024, 15:17 | Blog
Paolo Tarantino: Reflecting on debates in Napoli and Bridge2024
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, retweeted a post by Toni Choueiri,…
Dec 2, 2024, 22:27 | Insight
Survival Outcomes with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a recent article by Peter Schmid…
Dec 2, 2024, 18:09 | Insight
Paolo Tarantino: Excited to present the results of 4 studies at SABCS24
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X: “10 days to…
Dec 2, 2024, 12:31 | Insight
10 presentations not to miss from SABCS 2024 suggested by Paolo Tarantino
The SABCS 2024 (San Antonio Breast Cancer Symposium) will take place from December 10th to…
Nov 30, 2024, 23:26 | Insight
Is Carboplatin needed for the neoadjuvant treatment of HER2 positive Breast cancer?
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a recent by Xiu-Chun Chen on…
Nov 30, 2024, 14:02 | Insight
First Results of the Dutch SONIA Trial on CDK4/6 Inhibitors
Evaluating the Impact of CDK4/6 Inhibitors in First- and Second-Line Endocrine Therapy for HR+, HER2-…
Nov 24, 2024, 19:37 | Insight
Isabella Michelon: Meta-analysis of 2000+ patients with HER2-low and MBC
Isabella Michelon, 6th year medical student at the Catholic University of Pelotas, shared a recent…
Nov 17, 2024, 01:10 | Blog
Paolo Tarantino: Moderating a Medscape symposium focused on HR+/HER2 at SABCS24
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn: "HR+/HER2- is…
Nov 16, 2024, 18:42 | Blog
Paolo Tarantino: Focusing on HR+/HER2- Breast Cancer
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “HR+/HER2- is the…
Nov 13, 2024, 08:27 | Insight
Paolo Tarantino: The promise and challenges of response-adapted trials in breast oncology
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent…
Nov 12, 2024, 18:55 | Insight
Jayant Gadrey: Analysis of ongoing clinical trials of ADCs for patients with breast cancer brain metastases
Jayant Gadrey, Resident Physician at the Tufts Medical Center, shared a post on X by…
Nov 12, 2024, 18:43 | Insight
Paolo Tarantino: Could ADCs be safely administered subcutaneously?
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Could ADCs…
Nov 7, 2024, 16:03 | Insight
The journey of ADCs is a story of perseverance
An article by Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc., was recently…
Nov 6, 2024, 10:20 | Blog
Paolo Tarantino: Live discussion on the evolving role of ADCs across tumor histologies
Paolo Tarantino, Research Fellow at The Dana-Farber Cancer Institute, shared a post on X: "Join us tomorrow…
Nov 5, 2024, 15:59 | Blog
Elizabeth McKenna: The November issue of Cancer Discovery is now online
Elizabeth McKenna posted on X: "I'm so excited that the November issue of Cancer Discovery…
Nov 5, 2024, 15:51 | Blog
Paolo Tarantino: Honored to moderate the SABCS 2024 People’s Choice session
Paolo Tarantino posted on X: "Honored to moderate the SABCS 2024 People’s Choice session on…
Nov 4, 2024, 15:31 | Insight
Do patients with small ER+ tumors with high genomic risk benefit from chemotherapy?
An article by Florentine Hilbers, Postdoctoral Researcher at The Netherlands Cancer Institute, was recently mentioned by…
Nov 4, 2024, 14:04 | Insight
Raffaele Colombo: Insights from October: Advances in ADC research and cancer therapeutics
Raffaele Colombo shared a post on LinkedIn: "October was extremely busy yet incredibly rewarding: With Jamie…
Nov 4, 2024, 13:32 | Insight
Paolo Tarantino: The SERENA-2 phase 2 trial of camizestrant vs fulvestrant is out
Paolo Tarantino, Research Fellow at The Dana-Farber Cancer Institute, shared on X: “The SERENA-2 phase…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Nov 1, 2024, 07:37 | Blog
Paolo Tarantino: ADCs combine the potency of chemotherapy with the PK of mAbs
Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "ADCs combine the potency…
Oct 29, 2024, 13:05 | Insight
Paolo Tarantino: My 100th scientific publication
Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "It turns out…
Oct 28, 2024, 08:58 | Insight
Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…
Oct 27, 2024, 11:29 | Blog
Behind the Journey of ADCs by Raffaele Colombo
Raffaele Colombo posted on X about recent paper by him as first author titled "The…
Oct 26, 2024, 15:59 | Insight
Jean-Charles Soria: Key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs
Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a post…
Oct 26, 2024, 12:57 | Societies
Highlights from the 36th EORTC-NCI-AACR Symposium 2024
The 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics was held at the…
Oct 26, 2024, 11:58 | Blog
Jennifer Wargo on immunotherapy and microbiome at ENA Symposium 2024
Paolo Tarantino shared a post on X: ''Wonderful ENA Symposium 2024 keynote lecture on immunotherapy…
Oct 26, 2024, 09:26 | Blog
Paolo Tarantino: Honored to co-chair the New Drugs on the Horizon Session at the EORTC-NCI-AACR Triple Meeting
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn: "Such a honor to…
Oct 25, 2024, 16:47 | Blog
Key milestones and insights from the evolution of antibody-drug conjugates - Zymeworks Inc.
Zymeworks Inc. shared a post on Linkedin: ''We're proud to share a recent publication in…
Oct 25, 2024, 15:45 | Blog
Paolo Tarantino: Rational KRAS inhibitor combinations by Sandra Misale at ENA Symp 24
Paolo Tarantino, Research Fellowship Scholar at Dana-Farber Cancer Institute, shared a post on X: "Terrific talk…
Oct 25, 2024, 13:16 | Insight
Elizabeth McKenna: An overview of the past 4 decades of development of ADC’s
Elizabeth McKenna, Executive Editor of Cancer Discovery at American Association for Cancer Research, shared on…
Oct 25, 2024, 11:48 | Blog
Paolo Tarantino: Anticipated evolutions in the assessment of MRD to guide cancer treatment
Paolo Tarantino shared a post on X: ''ENASymp24 day 3: Heather Parsons from Dana-Farber’s Breast…
Oct 25, 2024, 11:41 | Blog
Raffaele Colombo: Honored to discuss ADCs at the ENASymp24
Raffaele Colombo shared a post by Sandra Misale, Assistant professor at Sidney Kimmel Comprehensive Cancer…
Oct 25, 2024, 08:51 | Blog
Nirmit Kumar: Great overview of the history of Antibody Drug Conjugates by Raffaele Colombo et al.
Nirmit Kumar, Senior Global Medical Strategy Leader at AstraZeneca, shared a post by Paolo Tarantino…
Oct 23, 2024, 14:45 | Blog
Paolo Tarantino: How do we build a new generation of safer and more active ADCs for treating cancer
Paolo Tarantino and Raffaele Colombo shared posts on X, about recent paper published in Cancer…
Oct 23, 2024, 10:40 | Insight
Paolo Tarantino: Final iDFS results from NATALEE published in Annals of Oncology
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared…
Oct 22, 2024, 10:18 | Blog
An extensive overview on precision medicine by Paolo Tarantino and Sara Tolaney
Florez Lab shared a post on X: ''Dr. Paolo Tarantino and Dr. Sara Tolaney are…
Oct 21, 2024, 19:21 | Blog
ESMO E-Learning: Management of HER2-Low Breast Cancers by Paolo Tarantino
Paolo Tarantino shared a post on LinkedIn: ''Our understanding of HER2-low expression as a biomarker…
Oct 21, 2024, 15:09 | Insight
Highlights from the 6th Annual Precision Medicine Symposium
The 6th Annual Precision Medicine Symposium took place from October 18th and 19th 2024. It…
Oct 20, 2024, 19:09 | Insight
Paolo Tarantino: Precision medicine for HR+ metastatic breast cancer: from hope to reality in little more than 5 years
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared on LinkedIn: “Precision medicine for HR+…
Oct 20, 2024, 18:31 | Blog
Paolo Tarantino: Terrific TNBC session in Hudson, NY
Paolo Tarantino shared the following on LinkedIn: “Terrific TNBC session in Hudson, NY. I had…
Oct 19, 2024, 16:37 | Drugs
Gilead Sciences has voluntarily withdrawn Trodelvy from the U.S. market
Gilead Sciences announced the voluntary withdrawal of its drug Trodelvy for bladder cancer after it…
Oct 17, 2024, 18:06 | Insight
Paolo Tarantino: We cure breast cancer every day better
Paolo Tarantino shared a post on LinkedIn: "The latest EBCTCG meta-analysis of over 150.000 patients…
Oct 17, 2024, 15:58 | Insight
Paolo Tarantino: We desperately need a biomarker to refine treatment for early-stage TNBC
Paolo Tarantino shared a post on X about a recent paper by M. Martín et…
Oct 13, 2024, 17:58 | Blog
Raffaele Colombo: Excited to be presenting ADCs at the 36th ENA symposium
The 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will be held in person…
Oct 12, 2024, 14:35 | Blog
Paolo Tarantino: EBCTCG analysis of breast cancer patients outcomes over two decades
Paolo Tarantino shared on X: "What is the actual impact of breast cancer clinical research…
Oct 12, 2024, 10:30 | Insight
FDA Approves Inavolisib with Palbociclib and Fulvestrant for Advanced Breast Cancer
On October 10, 2024, the FDA approved inavolisib (Itovebi, Genentech, Inc.) in combination with palbociclib…
Oct 11, 2024, 13:35 | Insight
Paolo Tarantino: ADCs bring us together in the fight against cancer
Paolo Tarantino shared a post on X: “ADCs bring us together in the fight against…
Oct 11, 2024, 08:15 | Insight
Managing ADC Toxicities on Lung Cancer Considered
IASLC shared a post on X: “Anti Drug Conjugates represent a new way of treating…
Oct 9, 2024, 16:03 | OncoDaily Pulse
Inside OncoDaily Party Barcelona
On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in Barcelona, Spain.…
Oct 8, 2024, 17:26 | Insight
Paolo Tarantino: The largest HER2-low sub-analysis of a RCT led by Guilherme Nader-Marta
Paolo Tarantino shared a recent article by Guilherme Nader-Marta et al. published in Breast Cancer…
Oct 4, 2024, 15:15 | Blog
Paolo Tarantino: An interesting biomarker study of DB04. Two notable findings at ESMO24
Paolo Tarantino shared a post on X: "Among the many great ESMO24 posters there was…
Oct 4, 2024, 15:09 | Blog
Phase 3 EVER-002 trial is out
Paolo Tarantino shared an article by Binghe Xu on X: "Phase 3 EVER-002 trial (also…
Oct 4, 2024, 10:15 | Blog
The first prospective trial of sacituzimab govitecan (+ trastuzumab) after T-DXd for HER2+ MBC
Paolo Tarantino shared a post by Dana-Farber’s Breast Oncology Center on X, adding: "There’s few open questions as…
Oct 1, 2024, 18:35 | Blog
Paolo Tarantino: A Bridge Between Chemotherapy of the Past and the Biological Therapies of the Present
Paolo Tarantino shared on X: "Conjugated Antibodies: A Bridge Between Chemotherapy of the Past and…
Oct 1, 2024, 17:18 | Blog
Paolo Tarantino: Feels like yesterday when I first stepped into Dana-Farber Cancer Institute
Paolo Tarantino shared a post on X: "It feels like yesterday when I first stepped…
Oct 1, 2024, 09:29 | Blog
Paolo Tarantino's ESMO24 top 5 breast cancer presentations and takeaway messages
Paolo Tarantino shared a post by Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, on X, adding:…
Sep 29, 2024, 15:48 | Blog
Elisabetta Bonzano: Dual HER2 inhibition, mechanisms of synergy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: "Dual HER2 inhibition:…
Sep 29, 2024, 15:43 | Blog
Paolo Tarantino: The ratio of enrollment to industry-sponsored trials has doubled between 2008-2022
Paolo Tarantino shared the following on X: “Out in JCO: the ratio of enrollment to…
Sep 28, 2024, 14:00 | Blog
Paolo Tarantino: How do the results of DESTINY-Breast06 change our practice?
Paolo Tarantino shared on LinkedIn: "How do the results of DESTINY-Breast06 change our practice? Should…
Sep 26, 2024, 16:11 | Blog
Chandler Park: Learning the latest cutting edge data to help our cancer patients at ESMO 24
Chandler Park shared a post on Linkedin: ''ESMO was FUN! Loved learning the latest cutting…
Sep 26, 2024, 14:19 | Blog
Paolo Tarantino: ADC stability does not equal ADC tolerability
Paolo Tarantino shared a post by Raffaele Colombo, on X, adding: ''Antibody-drug conjugate (ADC) stability…
Sep 26, 2024, 14:07 | Blog
Paolo Tarantino: Why didn’t Datopotamab Deruxtecan improve OS in HR+/HER2- metastatic breast cancer
Paolo Tarantino shared a post on X: ''Why didn’t Datopotamab Deruxtecan improve overall survival in hormone…
Sep 23, 2024, 16:12 | Insight
Giuseppe Banna: How ADCs are revolutionizing patient outcomes in real-time
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared on LinkedIn: “Join…
Sep 23, 2024, 11:36 | Blog
OncoDaily Party Barcelona
On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in…
Sep 23, 2024, 09:00 | Insight
Theodoros Kontoulis: Heterogeneity of residual disease (RD) after NACT in breast cancer
Theodoros Kontoulis shared on LinkedIn: “Most viewed in the last 7 days from JAMA Oncology:…
Sep 21, 2024, 01:25 | Insight
Paolo Tarantino: 10 facts to know to prepare for the rise of ADCs
Paolo Tarantino shared on X: “ADCs are among the most rapidly expanding treatment modalities in…
Sep 20, 2024, 06:22 | Blog
Paolo Tarantino: Steroids are the mainstay for treating ADC-induced ILD
Paolo Tarantino shared a post on X by Sarah Sammons adding: "Agree! Steroids are the…
All: 312 Posts: 1 - 100
Special Coverage